Anti-AXL CAR mRNA-LNP

AXL is a transmembrane receptor tyrosine kinase from the TAM family, encoded by the AXL gene. The extracellular domain of AXL contains two type III fibronectin and two immunoglobulin-like motifs, and its kinase domain can be phosphorylated by dimerization after binding to its ligand, growth arrest specificity 6 (Gas6), triggering a downstream signaling cascade. AXL is thought to be involved in many cellular functions in various cell types. In cancer cells, AXL signaling specifically alters tissue through AXL dysregulation. Overexpression of AXL is known to trigger tumor cell growth, survival, invasion, metastasis, angiogenesis, epithelial-mesenchymal transition, and immunosuppression. This overexpression is thought to be associated with treatment resistance and poor prognosis. AXL has emerged as a key facilitator of immune evasion and drug resistance in cancer cells, leading to invasive and metastatic cancers. This product is designed as a tool for the delivery and expression of anti-AXL CAR mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-AXL CAR mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The anti-AXL CAR in this product is approximately 56 kD and consists of anti-AXL scFv (single-chain variable fragment) linked to a second-generation CAR (chimeric antigen receptor) containing the CD8 hinge and transmembrane domain and 4-1BB and CD3ζ signaling domains. The full-length amino acid sequence of this anti-AXL CAR mRNA-LNP product is available upon request.